Banerjee Antara, Bizzaro Debora, Burra Patrizia, Di Liddo Rosa, Pathak Surajit, Arcidiacono Diletta, Cappon Andrea, Bo Patrizio, Conconi Maria Teresa, Crescenzi Marika, Pinna Claudia Maria Assunta, Parnigotto Pier Paolo, Alison Malcolm R, Sturniolo Giacomo Carlo, D'Incà Renata, Russo Francesco Paolo
Department of Surgery, Oncology and Gastroenterology, Gastroenterology/Multivisceral Transplant Unit, University Hospital Padova, Via Giustiniani 2, Padova, 35128, Italy.
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131, Padova, Italy.
Stem Cell Res Ther. 2015 Apr 16;6(1):79. doi: 10.1186/s13287-015-0073-6.
Inflammatory bowel diseases (IBD) are complex multi-factorial diseases with increasing incidence worldwide but their treatment is far from satisfactory. Unconventional strategies have consequently been investigated, proposing the use of cells as an effective alternative approach to IBD. In the present study we examined the protective potential of exogenously administered human umbilical cord derived mesenchymal stem cells (UCMSCs) against Dextran Sulfate Sodium (DSS) induced acute colitis in immunodeficient NOD.CB17-Prkdc (scid)/J mice with particular attention to endoplasmic reticulum (ER) stress.
UCMSCs were injected in NOD.CB17-Prkdc (scid)/J via the tail vein at day 1 and 4 after DSS administration. To verify attenuation of DSS induced damage by UCMSCs, Disease Activity Index (DAI) and body weight changes was monitored daily. Moreover, colon length, histological changes, myeloperoxidase and catalase activities, metalloproteinase (MMP) 2 and 9 expression and endoplasmic reticulum (ER) stress related proteins were evaluated on day 7.
UCMSCs administration to immunodeficient NOD.CB17-Prkdc (scid)/J mice after DSS damage significantly reduced DAI (1.45 ± 0.16 vs 2.08 ± 0.18, p < 0.05), attenuating the presence of bloody stools, weight loss, colon shortening (8.95 ± 0.33 cm vs 6.8 ± 0.20 cm, p < 0.01) and histological score (1.97 ± 0.13 vs 3.27 ± 0.13, p < 0.001). Decrease in neutrophil infiltration was evident from lower MPO levels (78.2 ± 9.7 vs 168.9 ± 18.2 U/g, p < 0.01). DSS treatment enhanced MMP2 and MMP9 activities (>3-fold), which were significantly reduced in mice receiving UCMSCs. Moreover, positive modulation in ER stress related proteins was observed after UCMSCs administration.
Our results demonstrated that UCMSCs are able to prevent DSS-induced colitis in immunodeficient mice. Using these mice we demonstrated that our UCMSCs have a direct preventive effect other than the T-cell immunomodulatory properties which are already known. Moreover we demonstrated a key function of MMPs and ER stress in the establishment of colitis suggesting them to be potential therapeutic targets in IBD treatment.
炎症性肠病(IBD)是复杂的多因素疾病,在全球范围内发病率不断上升,但其治疗效果远不能令人满意。因此,人们研究了非常规策略,提出使用细胞作为治疗IBD的有效替代方法。在本研究中,我们检测了外源性给予的人脐带间充质干细胞(UCMSCs)对葡聚糖硫酸钠(DSS)诱导的免疫缺陷NOD.CB17-Prkdc(scid)/J小鼠急性结肠炎的保护潜力,特别关注内质网(ER)应激。
在给予DSS后的第1天和第4天,通过尾静脉将UCMSCs注射到NOD.CB17-Prkdc(scid)/J小鼠体内。为了验证UCMSCs对DSS诱导损伤的减轻作用,每天监测疾病活动指数(DAI)和体重变化。此外,在第7天评估结肠长度、组织学变化、髓过氧化物酶和过氧化氢酶活性、金属蛋白酶(MMP)2和9的表达以及内质网(ER)应激相关蛋白。
在DSS损伤后,将UCMSCs给予免疫缺陷的NOD.CB17-Prkdc(scid)/J小鼠,显著降低了DAI(1.45±0.16对2.08±0.18,p<0.05),减轻了血便、体重减轻、结肠缩短(8.95±0.33 cm对6.8±0.20 cm,p<0.01)和组织学评分(1.97±0.13对3.27±0.13,p<0.001)。较低的MPO水平(78.2±9.7对168.9±18.2 U/g,p<0.01)表明中性粒细胞浸润减少。DSS治疗增强了MMP2和MMP9的活性(>3倍),而在接受UCMSCs的小鼠中显著降低。此外,给予UCMSCs后,观察到ER应激相关蛋白的正向调节。
我们的结果表明,UCMSCs能够预防免疫缺陷小鼠的DSS诱导的结肠炎。使用这些小鼠,我们证明了我们的UCMSCs除了具有已知的T细胞免疫调节特性外,还具有直接的预防作用。此外,我们证明了MMPs和ER应激在结肠炎发生中的关键作用,表明它们是IBD治疗中的潜在治疗靶点。